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Interventions to mitigate the impact of HIV infection in key populations in sub-Saharan Africa 
Stephen Bambeiha Asiimwe 
Abstract 
In sub-Saharan Africa (SSA), the region with the world’s highest HIV prevalence, antiretroviral therapy 
(ART) has recently reduced AIDS-related deaths.  However, death rates still remain unacceptably high, as 
do the numbers of new HIV infections.  HIV treatment is also often provided by stand-alone HIV clinics, 
distinct from other healthcare services.  As the people living with HIV (PLWH) start to survive into older 
age, adequately addressing emerging challenges, including but not limited to age-related diseases and 
disabilities, will require more integration for HIV- and non-HIV services.  Whereas ART, especially early 
ART for all HIV-infected patients, is the single most important intervention against HIV-related mortality 
and morbidity, the persistence of some complications (e.g., HIV-associated neurocognitive disorder 
[HAND]) and high rates of residual mortality in the ART era suggest that additional interventions are 
needed.   
In the first chapter of my dissertation, I present a comparison of the cognitive scores of PLWH in a rural 
community in South Africa and HIV-negative comparators in the same community.  Although adverse 
cognitive outcomes have been reported in clinical studies PLWH, no prior population-based studies in 
SSA have compared cognitive functioning among PLWH and HIV-negative comparators. The baseline 
data of participants in the “Health and Aging in Africa: A Longitudinal Study of an INDEPTH 
Community in South Africa” (HAALSI), a population-based cohort in rural Agincourt, Mpumalanga, 
northeast South Africa, were analyzed.  Participants, who are men and women aged at least 40 years.  
Cognitive scores on a conventional instrument assessing orientation, immediate and delayed recall, and 
numeracy for 4,560 participants, and a novel instrument (the Oxford Cognitive Screen [OCS]-Plus), 
assessing memory, language, visual-spatial ability, and executive functioning for 1,997 participants were 
used to measure cognitive functioning.  We used linear regression to compare composite cognitive scores 
between PLWH and HIV-negative participants, and among PLWH, anti-retroviral therapy (ART) users 
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versus non-users. Multilevel (random-intercepts) linear models assessed domain-specific associations on 
the OCS-Plus.  Estimates were adjusted for age, gender, education, country of birth, father’s occupation, 
household asset index, and ever-consumed alcohol.  Of 4,560 participants, 1,048 were HIV positive (719 
used ART).  PLWH averaged 0.06 (95% CI: 0.01 to 0.12) standard deviation units higher scores on the 
conventional cognitive battery than HIV-negative participants.  However, PLWH averaged 0.03 (95% CI, 
-0.08 to 0.03) standard deviation units lower scores on the OCS-plus instrument, the result not reaching 
statistical significance.  Among PLWH, ART use did not predict cognition.  There were no domain-
specific cognitive effects from HIV or ART using the OCS-Plus measures.  PLWH thus had higher 
cognitive function scores than HIV-negative comparators on a conventional cognitive assessment but not 
on a novel measure designed for low-literacy settings.   
In the second chapter, I present an assessment of the association between HIV status and ART and age-
related disability in the HAALSI baseline sample. We specifically evaluated whether these associations 
depend on body mass index (BMI).  Although antiretroviral therapy (ART) use could mitigate risk of age-
related disability among people living with HIV (PLWH), ART often causes weight-gain and could 
counter-intuitively increase risk of disability through elevated BMI.  The baseline data of 4552 
individuals (1040 with HIV and 3512 without HIV) were analyzed.  Primary predictors were HIV status 
and ART use.  The outcome was disability in at least one of five basic ADLs (walking across the room, 
getting up from bed, dressing, bathing and using the toilet).  BMI, calculated from measured weights and 
heights, was considered in categories of underweight (<18.5kg/m2), normal BMI (18.5 to <25), 
overweight (25 to <30) and obese (≥30).  We estimated prevalence differences in the outcome comparing 
PLWH to participants without HIV, and among PLWH, ART users to non-users.  Additional models in 
PLWH compared virally suppressed ART users vs. unsuppressed ART users vs. ART non-users.  We 
assessed BMI effects using its interaction with HIV and ART use.  All regression models were adjusted 
for age and sex; more comprehensively adjusted models added education, father’s occupation, country of 
origin, and alcohol use.  Among the 4552 study participants, 11.9 % reported at least one ADL disability.  
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PLWH had lower prevalence of obesity (21% among PLWH vs 30% in participants without HIV) but 
higher prevalence of underweight (7.4% among PLWH vs 4.6% among participants without HIV).  
Among PLWH, those who were underweight had 13.3 percentage points (95% CI: 3.8 to 22.8) higher 
prevalence of an ADL disability than those with normal BMI.  Those with obesity had 2.9 percentage 
points (95% CI: -2.3 to 8.1) higher prevalence of an ADL disability than those with normal BMI, the 
result not reaching statistical significance.  Among the 69% of PLWH who were ART users, those with 
underweight had 13.7 percentage points (95% CI: 2.8 to 24.4) higher prevalence of ADL disability than 
normal-weight ART users.  Those with obesity had 1.2 percentage points higher prevalence of an ADL 
disability (95% CI: -4.3 to 6.9) higher prevalence of an ADL than those with normal BMI, the result not 
statistically significant.  Underweight participants thus had increased prevalence of ADL disability, but 
overweight and obese individuals did not. We find no evidence that weight increases associated with ART 
use are likely to increase disability.   
In the third and final chapter, I assess the sufficiency of ART in eliminating excess mortality from 
Kaposi’s sarcoma (KS), an HIV-associated cancer, among HIV-infected adults initiating ART in Uganda.  
Despite KS being among the most common adult malignancies in the region following the onset of the 
HIV epidemic, approaches to its therapeutic management have largely been extrapolated from high-
resource settings such as the US.  In particular, antiretroviral therapy (ART) is often used alone for the 
initial management of persons with KS who do not have immediately life-threatening complications 
without any direct evidence in African patients of the effectiveness of this strategy.  Among HIV-infected 
participants in Uganda who were initiated on ART, we compared those with biopsy-confirmed KS to 
those without KS.  We used a directed acyclic graph (DAG) to identify relevant confounders, which were 
measured identically in both groups, in order to test the hypothesis that the participants with KS have 
excess mortality.  Survival was determined over 4 years with dedicated attention to decrease loss to 
follow-up by actively tracking lost participants in the community.  We evaluated 224 participants with KS 
and 683 participants without KS who were initiated on ART between 2005 and 2013.  Males were 37%, 
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median values were; age 34 (IQR 28 to 40), CD4+ T-cell count 158 cells/mm3 (IQR 76 to 263), and 
plasma HIV RNA level 5.2 log10copies/ml (IQR 4.6 to 5.6).  In the unadjusted analysis, mortality at 1 
year was 18.8% in those with KS and 3.9% in those without KS; at 4 years, mortality was 30.4 % and 
8.2% respectively.  After adjustment using proportional hazards regression for age, sex, asset holding, 
history of tuberculosis, history of cryptosporidial diarrhea, history of esophageal candidiasis, physical 
health summary score, body mass index, hemoglobin, CD4+ T cell count, plasma HIV RNA level, and 
calendar date of ART initiation, participants with KS had a 5.0-fold (95% CI 2.5-10.0; p <0.001) higher 
rate of death in the first year after start of ART than those without KS and a 2.9-fold (95% CI 1.2-7.0, 
p=0.020) higher rate of death thereafter.  In a prototypical patient, the absolute difference in risk of death 
among those with KS +20% at 4 years.  Even in this population of patients with KS who did not have 
immediately life-threatening complications, use of ART alone did not eliminate excess mortality from 
KS.   
The findings of this work do suggest the need for additional interventions over and above ART to address 
HIV-related morbidity and mortality in SSA.  We did not find evidence that PLWH are likely to have 
increased burden of cognitive impairment or disability.  However, future studies should explore cognitive 
and disability trajectories in longitudinal data to further evaluate associations with HIV and ART use, 
especially early ART, to guide intervention.    
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Chapter 1 : Cognitive differences associated with HIV serostatus and 
antiretroviral therapy use in a population-based sample of older adults in 
South Africa 
 
  
2 
 
Background 
Despite the now widespread use of antiretroviral therapy (ART) among people living with HIV (PLWH), 
HIV-associated neurocognitive disorder (HAND) remains a prevalent HIV-related complication [1].  
HAND is sub-classified according to its progression as asymptomatic neurocognitive impairment (ANI), 
mild neurocognitive disorder (MND), or HIV-associated dementia (HAD) [2].  In the US, estimates of 
cumulative incidence of MND in ART-treated PLWH approximately one year after ART initiation ranged 
from 16% to 21%, and were higher than estimates of similar neurocognitive disorder in HIV-negative 
individuals [3, 4].  Previous clinical studies in South Africa reported high prevalence of HAND among 
PLWH, ranging from 53% [5] to 67% [6].  However, there is no prior population-based study comparing 
neurocognitive impairment among PLWH (ART users and non-users) and HIV-negative comparators in 
sub-Saharan Africa (SSA) [7].   
The high burden of HAND in the ART era suggests that interventions over and above ART may be 
required to address the problem.  However, ART is now available in the public health sector for most of 
SSA [8, 9], and its effects on cognition in HIV-affected populations ought to be investigated directly.  
Studies from high-income countries suggest persistence of cognitive impairment in the ART era at rates 
comparable to those in the pre-ART era.  However, some studies suggest change in presentation from 
predominantly motor skills, cognitive speed, and verbal fluency impairment in the pre-ART era, to 
predominantly memory and executive function impairment in the ART era, suggesting possible domain-
specific effects from HIV and/or ART [10].  Even if ART does not influence cognition overall, 
identifying domain-specific effects of HIV and/or ART on cognition may advance our understanding of 
the mechanisms of cognitive impairment, potentially guiding clinical care and future research. 
The context may also modify the effects of HIV and ART on cognition.  For example, in SSA, PLWH 
often begin ART with severe levels of immunosuppression [11].  Such biological characteristics – as well 
as a wide range of socio-structural characteristics (e.g., social-support)– could lead to different 
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distributions of HAND in SSA setting compared to other contexts, and possibly different impacts from 
ART [12].   
Measurement of cognitive function is challenging in SSA.  Conventional cognitive performance tests 
developed for high-literacy settings, may not be appropriate in low-literacy settings [13, 14].  Previous 
work in the “Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South 
Africa” (HAALSI) has thus developed a novel tablet-based cognitive performance instrument, the Oxford 
Cognitive Screen (OCS-Plus), designed to be more appropriate for a low-literacy setting.  Unlike most 
conventional tests, which rely on language and numeracy skills, the OCS-Plus instrument relies more on 
visual and auditory abilities [15, 16].   
We used HAALSI baseline data to describe in a cross-sectional analysis the population distribution of 
cognitive outcomes in a community of older PLWH residing in SSA.  Our specific aims were to: (i) 
compare the cognitive performance of PLWH and HIV-negative comparators; (ii) among PLWH, 
compare cognitive performance between ART users and non-users, and (iii) evaluate the performance of 
specific cognitive assessment instruments.  We hypothesized that: (i) PLWH would have lower overall 
cognitive scores due to negative effects of HIV on cognitive performance; (ii) among PLWH, ART users 
would have higher scores due to beneficial effects of ART on cognitive performance; (iii) the associations 
of HIV and ART with cognition would vary between the conventional and the novel OCS-Plus measures; 
and iv) the associations of HIV and ART with cognitive scores would also vary across different domains 
of the OCS-Plus measure. 
Methods 
Sample 
Participants were part of the HAALSI cohort, a population-based study designed to measure the health 
and well-being of adults 40 years and older in the rural Agincourt sub-district, Mpumalanga province, 
northeast South Africa [16].  HAALSI participants were sampled from the 2013 census round of the 
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existing MRC/Wits-Agincourt Health and socio-Demographic Surveillance System (HDSS), which is part 
of the International Network for the Demographic Evaluation of Populations and their Health (INDEPTH) 
[17].  The HAALSI study enrolled 5,059 men and women who were 40 years or older on July 1, 2014 
[17-19].  For this analysis, we restricted our sample to 4,582 participants who provided dried blood spots 
and consented to HIV tests.  We excluded participants who had indeterminate HIV test results (N = 22) 
and HIV-positive participants whose treatment status could not be established (N = 8) and analyzed 4,560 
individuals (90% of the original 5,059 HAALSI participants) (Figure 1.1). 
Given the prevalence of low-literacy in the sampled population, about half of HAALSI participants were 
randomly selected to participate in a novel cognitive function assessment, the OCS-plus instrument, 
which was designed for use in low-literacy settings [15].  Sampling for completion of this assessment was 
stratified by age and sex to allow appropriate representation.  
Predictor measurement 
HIV-infection was assessed using PCR tests on dried blood spots (DBS) (Vironostika Uniform 11, 
Biometrica, France).  Viral load measurements (Biomeriux NucliSens, Durham, NC, USA) were 
performed on those testing HIV-positive.  DBS samples for those testing HIV-positive were also tested 
for emtricitabine (FTC) and lamivudine (3TC).  PLWH typically receive either FTC or 3TC but not both 
of these commonly used antiretroviral drugs [16, 18].  We regarded all HIV-positive individuals who 
were either virally suppressed or positive on any antiretroviral drug as ART users.  PLWH who were 
virally suppressed but negative for antiretroviral drugs (N=52) were classified as ART users; we did not 
believe that such individuals would be suppressed for reasons other than ART [20].   
Outcome measurement 
For the conventional cognitive function measure, a previously constructed score assessing orientation, 
memory, and numeracy was used [21].  Orientation assessed: current year, month, date, and South 
African president (4 points).  Memory assessed immediate word recall (list of 10 words in xiTsonga, the 
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local language, read out by the interviewer), and delayed word recall (read from the same 10-word list 
after 4 to 5 minutes of unrelated questions) (20 points).  Numeracy assessed ability to count from 1 to 20 
(forward counting) (1 point).  Those able to count were further asked to complete the fourth digit of the 
sequence 2, 4, 6, ... (1 point).  Scores were combined into a z-standardized latent variable via 
confirmatory factor analysis in Mplus [21, 22]. 
Nearly half of the participants in this older-age community-representative sample were illiterate.  We thus 
explored the novel Oxford Cognitive Screen (OCS)-plus measures, intended to be more appropriate than 
conventional batteries in low-literacy settings, in a randomly selected smaller sample [15].   
We used 10 items from the OCS-Plus measures, designed to tap into distinct cognitive domains and 
minimize education- and literacy-related bias.  Previous (unpublished) factor analyses of the OCS-plus 
data in HAALSI suggested 4 underlying factors: memory, language/semantic knowledge, visuospatial 
ability and executive function.  The memory domain included a 5-word immediate recall task, delayed 
word recall (4-5 minute delay), and delayed word recognition, which tested ability to recognize words not 
retrieved during free recall (3 items, 5 points each).   
The language domain was measured by a picture naming task with 4 low-frequency target pictures; and a 
test of semantic knowledge (4 objects), requiring participants to point to a particular object or identify the 
object from a specific semantic category (2 items, 4 points each).   
The visuospatial domain included two tests of constructional praxis.  In one test, the respondent was 
asked to use a stylus to copy a complex object presented on the tablet screen (figure copy).  In another 
test, the object was briefly presented on the screen (2 seconds), and the respondent was asked to draw it 
from memory (figure recall).  In each test, the object had 7 defining elements, each scored for presence (1 
point), accuracy (1 point) and position (1 point) (2 items, 21 points each).   
The executive function domain consisted of three different versions of a non-verbal trails task, where 
respondents were asked to connect shapes on the tablet screen using different rules (a point for each 
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correct connection, 7 points maximum): first circles small to large, then squares large to small, and then 
alternating between circles and squares, decreasing in size for squares and increasing in size for circles (3 
items, 7 points each). 
Covariate measures 
We represented our assumptions regarding the underlying causal structure using a directed acyclic graph 
(Figure 1.2) in order to guide the selection of covariates into our regression models.  Covariate data 
collected during in-person interviews included father’s main occupation (manual labor vs. services vs. 
self-employed or business owner vs. professional vs. others), country of birth (South Africa vs. 
Mozambique or other), sex (male vs. female), age (years), education (no formal education vs. some 
primary education vs. some secondary education vs. secondary or more), ever consumed alcohol (yes vs. 
no), and asset index score (z-standardized score representing asset ownership, household quality and 
energy sources) [23].  As cardiovascular risk factors such as hypertension could also mediate effects of 
HIV and ART on cognition [18], we measured systolic blood pressure (SBP) and diastolic blood pressure 
(DBP).  Three measurements were taken two minutes apart with an electronic BP machine and the 
necessary cuff depending on the size of the participant (Omron, Kyoto, Japan).  The average from the last 
two measurements was used [16, 18].   
Analyses 
Descriptive analyses 
We assessed the distributions of scores on each cognitive instrument comparing PLWH to HIV-negative 
individuals, and in PLWH comparing participants currently using ART to those not using ART.   
The associations of HIV and ART use with cognitive function using conventional measures 
We used linear regression to predict scores on the conventional cognitive function battery with HIV status 
as the predictor.  We repeated this analysis using ART as the predictor, restricting to PLWH.  We 
controlled for two sets of covariates: model 1 included age, sex, country of birth, father’s occupation, 
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education, asset index, and alcohol consumption; model 2 additionally included SBP, DBP, and – when 
evaluating effects of ART – log-transformed viral load.   
Derivation of domain-specific measures from the OCS-Plus instruments 
We used R’s Lattice package to estimate and extract z-standardized factor scores representing the four 
cognitive function domains of memory, language, visuospatial ability, and executive functioning from the 
ten individual OCS-Plus cognitive test items (Figure 1.3) [24].   
Cognitive domain-specific effects of HIV and ART use 
To evaluate possible domain-specific effects from HIV/ART on cognition, we used a multi-level model 
(Equation 1) treating domain-specific z-scores on OCS-Plus instruments as distinct measures of 
cognitive function clustered within individuals. The model nested multiple cognitive assessments within 
individuals predicting each cognitive z-score outcome with indicator variables for each cognitive domain 
(memory, language, visuospatial ability, and executive functioning) and an interaction between these 
domains and the primary predictor (HIV or ART).  Numeric covariates were centered at their means. 
Specifically, letting Yij represent cognitive z-score of individual i on domain j, we estimated multilevel 
models such as (using the ART use exposure model as the example): 
Yij = β00 + Σβ1Mij + β2Ai + β3Ci + Σβ4Ai*Mij + μ0i + ε ij   (1) 
In this model, β00 would represent average score on the reference cognitive domain (which we specified 
as memory in all models) among ART non-users in the reference categories of categorical covariates with 
the mean values of numeric covariates.  Mij is a set of indicator variables representing the four cognitive 
function domains, and β1 represents the corresponding coefficients (deviations from mean score in the 
reference outcome of memory for each cognitive domain in ART non-users); because we estimated 4 
domains, there are 3 indicator variables and corresponding coefficients, which we suppress in equation 1. 
A is an indicator variable for treatment status and β2 is the estimated effect of ART on memory, β3 
represents coefficients for confounders, and β4 represents the set of coefficients indicating the differential 
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effect of ART on a given cognitive domain; these coefficients test the hypothesis that the effects of ART 
differ across cognitive domains.  Error terms μ0i (representing random variability between individuals) 
and ε ij (representing random variability within individuals) were assumed to be approximately normally 
distributed.   
Interaction between age and HIV in their association with HIV 
As age is strongly associated with cognitive function, we assessed for its interaction with HIV in 
predicting cognitive scores on the conventional measure and a simple average of the 4 domain-specific z-
standardized scores on the OCS-Plus instrument.  
Missing data 
For the analysis using the conventional measure of cognitive function, we conducted a complete-case 
analysis (only 92/4582 (2%) of participants had missing scores and less than 1% of participants were 
missing any covariate data).  Missing data in specific items on the OCS-Plus measure ranged from 0.8% 
on picture identification to 32% on figure copy.  We used multiple imputation to impute missing values 
on the OCS-Plus variables before confirmatory factor analysis and subsequent analyses.  Multiple 
imputation was implemented using the MICE package in R [25].  We used predictive mean matching to 
estimate missing values based on 5 nearest neighbors and created five copies of the dataset with missing 
values imputed under a missing-at-random assumption given a participant’s age, gender, education, asset 
index, country of origin, HIV test results, systolic blood pressure, diastolic blood pressure, alcohol ever 
consumption, and father’s occupation.  Subsequent analyses were performed on each of the imputed 
datasets and results pooled into a final estimate [26, 27]. 
Results 
Sample characteristics 
The HIV prevalence among those tested was 1040/4582 (23%).  PLWH were younger on average than 
HIV-negative participants (55 years [SD=10] vs. 64 years [SD = 13]), had slightly lower formal education 
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(41% vs. 47%), slightly lower systolic blood pressure mean = 130 (SD = 22) versus 140 (SD = 23) 
mmHg, and lower average score on the wealth and asset index, -0.31 (SD = 2.2) vs. 0.1 (SD = 2.4) (Table 
1.1).  Among the 1040 PLWH analyzed, 719 (69%) were ART users.  The ART users were like non-ART 
users with respect to all covariates except they presented with a much lower viral load (mean = 5874 
copies/ml, SD = 22610, in ART users versus 52300, SD = 250269 among non-ART users) (Table 1.1). 
Distributions of cognitive function measures 
PLWH had higher mean scores on the conventional cognitive function battery than HIV-negative 
participants.  The OCS-Plus scores were similar between groups except for trail tests, where PLWH had 
slightly higher scores (Table 1.2). 
Association of HIV status and ART treatment with cognitive scores on the conventional 
measure 
After adjustment for confounders, PLWH had slightly higher cognitive z-scores than HIV-negative 
participants on the conventional cognitive battery (β = 0.06; 95% CI, 0.01 to 0.12). Additional adjustment 
for systolic blood pressure and diastolic blood pressure did not significantly alter the results (Table 1.3).  
For context, in this sample a 1-year age increase was associated with a cognitive score difference of -
0.021 (95% CI, -0.018 to -0.023).   
Among PLWH, we did not find evidence for significant differences in cognitive score by ART use status.  
In a sensitivity analysis comparing PLWH using ART and PLWH not using ART to HIV negative 
individuals, there were no significant differences in cognitive scores between ART users and non-users, 
although both groups had higher scores on the conventional measure than HIV-negative individuals 
(Table 1.4). 
Association of HIV infection with cognitive function on the OCS-plus instrument 
In the multi-level model adjusting for covariates, there were no significant domain-specific interactions 
for the effects of HIV on cognition (Table 1.5).  In a model to estimate the overall effect of HIV and ART 
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on cognition using the OCS Plus instrument (dropping the measure by exposure interaction), PLWH had 
slightly lower cognitive scores than HIV-negative participants, although the result was not statistically 
significant (β = -0.03; 95% CI, -0.08 to 0.03).  Among PLWH, ART users had higher cognitive scores 
than non-ART users, but the confidence interval was wide and included the null (β = 0.05; 95% CI, -0.05 
to 0.15) (Table 1.5).  Similar findings were observed in additional models, where the outcome was a 
simple average of the scores on the 4 OCS-Plus domains (Table 1.6). 
Interaction between age and HIV in their association with cognitive score 
In the analysis using the conventional measure, older PLWH had higher cognitive scores than older 
participants without HIV (Figures 1.4 and 1.5).  In a model to predict scores on the conventional 
cognitive function measure, adjusting for covariates, and including an interaction term between centered 
age and HIV status, PLWH had higher overall cognitive scores (β = 0.11, 95% CI, 0.05 to 0.18) and the 
age-slope was slightly flatter (β = 0.01, 95% CI, 0.004 to 0.014).  In a similar model using the average of 
scores on the 4 OCS-Plus domains as the outcome, PLWH averaged lower scores on (β = -0.078, 95% CI, 
-0.14 to 0.001), though the result did not reach statistical significance, and there was no interaction 
between age and HIV status (β =-0.01, 95% CI, -0.01 to 0.001) (Table 1.7).   
Discussion 
This study presents, for the first time to our knowledge, a comparison of the cognitive function in older 
people by HIV status in SSA. The comparison was done in groups with similar sociodemographic 
characteristics, in an HIV hyperendemic community in rural South Africa.  We observed higher overall 
cognitive function scores among PLWH when cognition was measured by a conventional battery of 
questions commonly used in high-income countries. However, we did not observe differences in 
cognition when function was measured using the OCS-Plus instrument, which uses visual and auditory 
cues to minimize literacy-related bias in cognitive testing in low-literacy communities [18].  ART use was 
non-significantly associated with better cognitive outcomes among PLWH. 
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The finding that PLWH presented with higher overall cognitive function by the conventional battery was 
surprising.  Most prior evidence suggests that PLWH average lower cognitive function scores presumably 
because of adverse effects from HIV infection on cognition.  In a US study, older PLWH had slightly 
higher cumulative incidence of MND (5% vs. 3%) compared to HIV-negative participants [4].  For SSA, 
we did not find similar population-based studies, but in a hospital-based study of individuals with 
psychosis, PLWH were more likely to be cognitively impaired [28].   
Population-based studies of diabetes and hypertension in SSA have reported better outcomes for PLWH.  
In a previous study using HAALSI data, PLWH averaged lower SBP and lower prevalence of diabetes 
[18].  In a Ugandan study, HIV infection was associated with approximately 3.3 mmHg lower SBP and 
30% lower odds of hypertension [29]. These associations may be due to lower BMI among PLWH, since 
BMI is a risk factor for both hypertension and diabetes [30].   
Differential access to healthcare for PLWH compared to HIV negative comparators is also possible.  In a 
previous study using data from HAALSI, PLWH were more likely to have had their blood pressure and 
blood sugar measured, more likely to have received counseling on exercise, more likely to be aware of 
their hypertension status and, as such, more likely to have been treated [18].  In HAALSI, a large 
proportion (69%) of PLWH are receiving ART.  HIV care programs in SSA are often vertical programs 
that are more intensively managed, which may lead to better services than the general healthcare system 
serving individuals without HIV [31, 32].  It is unclear if these mechanisms might contribute to better 
cognitive outcomes for PLWH, and this may warrant future study.   
In addition to these possibilities, selective survival among PLWH may explain apparent cognitive 
advantage, if more vulnerable PLWH died before cross-sectional sampling of the HAALSI baseline data 
occurred.  A selected group of PLWH who are robust to the physical and cognitive consequences of HIV 
may then be sampled.  This mechanism is consistent with our analyses assessing for interaction between 
age and HIV on the conventional measure of cognitive function where older PLWH had higher cognitive 
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scores than HIV-negative comparators.  Future longitudinal studies are important to better understand this 
issue.   
Other selection processes influencing initial infection risk, sampling, or data availability also may shape 
cognitive patterns in the HAALSI sample.  For example, very old and very sick PLWH might not have 
been interviewed.  Cognitive advantage however was not observed among PLWH on the OCS-Plus 
measure, raising doubts on this mechanism.  Numerous unmeasured factors may also have influenced 
HIV infection and cognition since, despite adjustment for confounders, we cannot rule out the possibility 
of residual confounding in an observational study.  In particular, literacy bias could give advantage to 
PLWH if literacy differences are not adequately controlled for by adjustment for education level.  
Although the sample size in the OCS-Plus analysis was small leading to inconclusive results, findings 
using this measure were more consistent with our prior expectation of a cognitive disadvantage among 
PLWH.  Future studies using this measure and other novel cognitive function assessment tools designed 
to be more appropriate in low-literacy settings are recommended [33].  
Our results should not be interpreted as causal given the several competing alternative explanations. 
Regardless, even if not causal, our findings have important implications for policies aimed at providing 
care to aging cohorts of PLWH in SSA.  If PLWH are systematically more likely to have cognitive 
impairment, policies to provide for HIV treatment and management would need to be designed to 
accommodate such impairments.  If selective survival within PLWH means that we are only observing a 
small group of more robust survivors, then we do not know what the pattern of cognition would have 
been in the non-survivors.  Increased access to ART, especially if treatment occurs early in the course of 
HIV-infection, as is likely to happen with the current policy of “test and treat”, may eliminate such 
selective survival allowing for better future exploration of the effects of both HIV and ART on cognition.   
A cognitive advantage in PLWH on the other hand, if confirmed may mean that a growing number of 
older adults living with HIV may not necessarily cause an epidemic of HIV-associated dementia.  A 
broader range of interventions and programs to provide for ongoing management of HIV infection in 
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older adults may then be needed.  But even then, support to those with more severe cognitive impairment 
and/or their caregivers may be needed, since social programs to support elderly and cognitively impaired 
individuals are largely unavailable in SSA.  
 Our study provides unique data comparing HIV infected individuals to uninfected individuals with 
similar sociodemographic backgrounds in a setting of high HIV prevalence and where ART is now 
widely available through the public health sector.  Objective measures on HIV status and ART use, as 
well as multiple cognitive function measures add to the strengths of our observations, but due to their 
cross-sectional nature, the data do not necessarily describe causal effects of HIV on cognition.  We 
therefore recommend future longitudinal studies to further explore cognitive differences between HIV-
positive and HIV-negative individuals in this setting and to further develop measurement tools that may 
be more appropriate for this and similar settings.   
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Figure 1.1. Selection of analytic sample from participants in “Health and Aging in Africa: A 
Longitudinal Study of an INDEPTH Community in South Africa” (HAALSI)   
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Fig. 2.1a. HIV infection vs. cognitive performance 
 
Fig. 2.1b. ART vs. cognitive performance 
 
Figure 1.2. Directed acyclic graphs depicting possible relationships between HIV (2.1a) and ART (2.1b) 
and cognitive performance 
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Figure 1.3  Factor loadings from a confirmatory factor analysis of 10 items from the OCS-Plus measure 
of cognitive function in “Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community 
in South Africa” (HAALSI)   
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Figure 1.4. Age-HIV interaction in predicting cognitive score on the conventional measure by quartiles 
of age  
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Figure 1.5. Age-HIV interaction in predicting cognitive score on the conventional measure with age as a 
continuous variable 
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Table 1.1. Characteristics of baseline participants (N = 4560) in Health and Aging in Africa: A 
Longitudinal Study of an INDEPTH Community in South Africa (HAALSI), Agincourt, South Africa, 
2015 
Characteristic HIV-negative  
(N = 3512) 
All HIV-
positive  
(N = 1048) 
ART users 
(N=719) 
Non-ART 
users  
(N = 321) 
Age, years 64 (13)* 55 (10) 56 (10) 55 (11) 
Men (N, %) 1614 (46%) 483 (46%) 339 (47%) 140 (43%) 
Country of birth, N (%)     
   South Africa 2486 (71%) 683 (65%) 477 (66%) 202 (64%) 
   Mozambique/Other 1024 (29%) 363 (35%) 240 (33%) 119 (37%) 
Father’s occupation     
   Manual labor 1950 (56%) 558 (56%) 414 (58%) 169 (53%) 
   Services 349 (9.9%) 104 (9.9%) 78 (11%) 26 (8.1%) 
   Self-employed or business 111 (3.2% 34 (3.2% 22 (3.1%) 12 (3.7%) 
   Professional 302 (8.6%) 106 (10%) 73 (10%) 33 (10%) 
   Other 387 (11%) 130 (12%) 83 (14%) 46 (14%) 
   Don’t know or refused 412 (12%) 85 (8.1%) 48 (11%) 35 (11%) 
Education (N, %)     
   No formal education 1660 (47%) 429 (41%) 286 (40%) 141 (44%) 
   Some primary education 1225 (35%) 364 (35%) 263 (37%) 96 (30%) 
   Some secondary education 345 (9.8%) 162 (16%) 107 (15%) 54 (17%) 
   Secondary or more 272 (7.7%) 89 (8.5%) 60 (9.0%) 29 (8.3%) 
Ever consumed alcohol 1564 (46%) 470 (45%) 339 (47%) 128 (40%) 
Asset index score, mean 
(SD) 
0.10 (2.4) -0.31 (2.2) -0.22 (2.2) -0.48 (2.2) 
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Characteristic HIV-negative  
(N = 3512) 
All HIV-
positive  
(N = 1048) 
ART users 
(N=719) 
Non-ART 
users  
(N = 321) 
Systolic BP, mmHg 140 (23) 130 (22) 129 (22) 133 (22) 
Diastolic BP, mmHg 83 (13) 81 (13) 80 (13) 83 (12) 
Hemoglobin, mg/dl 12.7 (2.0) 12.1 (1.9) 12.1 (2) 12.2 (1.7) 
Viral load, copies/ml - 16191 
(136351) 
1499 
(11668) 
49034 
(242627) 
*Mean (SD)
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Table 1.2. Cognitive outcomes on conventional and OCS-Plus cognitive batteries, according to HIV 
status, HAALSI, Agincourt, South Africa, 2015. 
Measures 
HIV-negative 
(N=3512) 
All HIV-
positive  
(N=1048) 
HIV-positive 
ART users 
(N=719) 
HIV-positive 
ART non-
users (N=321) 
Conventional measures     
Orientation (N giving correct 
response) 
    
   Current date, N (%) 2382 (88%) 838 (80%) 579 (81%) 252 (79%) 
   Current month, N (% )  2749 (78%) 916 (87%) 633 (88%) 277 (86%) 
   Current year, N (%) 2506 (71%) 850 (81%) 583 (81%) 262 (82%) 
   Current president, N (%) 2794 (80%) 893 (85%) 619 (86%) 268 (84%) 
Word recall (number of words)     
   Immediate, median (IQR) 4 (3 to 5) 5 (3 to 6) 4 (3 to 6) 5 (3 to 6) 
   Delayed, median (IQR) 4 (2 to 5) 4 (3 to 5) 4 (3 to 5) 4 (3 to 5) 
Numeracy (N responding 
correctly) 
    
   Forward count (1 to 20), N (%) 2636 (75%) 867 (83%) 605 (84%) 256 (80%) 
   Skip pattern, N (%) 1892 (54%) 655 (63%) 452 (63%) 198 (62%) 
Cognitive score, mean (SD) -0.06 (0.99) 0.19 (0.94) 0.20 (0.92) 0.18 (0.99) 
OCS-Plus, correct responses, 
median (IQR) 
HIV-negative 
N = 1489 
All HIV-
positive  
N = 505 
HIV-positive 
ART users 
N=358 
HIV-positive 
ART non-
users N=150 
Executive function     
   Trails, circles 3 (1 to 6) 4 (2 to 7) 4 (2 to 7) 4 (1 to 6) 
22 
 
OCS-Plus, correct responses, 
median (IQR) 
HIV-negative 
N = 1489 
All HIV-
positive  
N = 505 
HIV-positive 
ART users 
N=358 
HIV-positive 
ART non-
users N=150 
   Trails, squares 3 (0 to 5) 4 (1 to 5) 3 (1 to 5) 4 (1 to 5) 
   Trails, mixed 3 (1 to 6) 4 (1 to 7) 4 (2 to 7) 4 (1 to 6) 
Language     
   Picture naming 3 (3 to 4) 3 (2 to 3) 3 (2 to 3) 3 (2 to 3) 
   Semantic pictures  3 (2 to 4) 3 (3 to 4) 4 (3 to 4) 3 (3 to 4) 
Visual-spatial ability     
   Figure copy  19 (17 to 20) 19 (16 to 20) 19 (16 to 20) 20 (17 to 21) 
   Figure recall  17 (12 to 19) 17 (12 to 19) 16 (12 to 19) 18 (14 to 20) 
Memory     
   First immediate word recall 3 (3 to 4) 4 (2 to 4) 4 (3 to 4) 3 (3 to 4) 
   Delayed word recall 3 (2 to 4) 3 (2 to 4) 3 (2 to 4) 3 (2 to 4) 
   Delayed word recognition 5 (4 to 5) 5 (4 to 5) 5 (4 to 5) 5 (4 to 5) 
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Table 1.3. Associations between HIV status, ART use, and the conventional cognitive battery z-score, 
HAALSI, Agincourt, South Africa, 2015. 
 Model 1* Model 2† 
HIV status (N = 4480)   
   HIV-Negative  Ref. Ref. 
   HIV-Positive (β, 95% CI) 0.06 (0.01 to 0.12) 0.07 (0.01 to 0.12) 
Treatment status among HIV-positive (N = 1020)  
   ART non-user  Ref. Ref. 
   ART user (β, 95% CI) -0.01 (-0.12 to 0.09) -0.05 (-0.20 to 0.10) 
 
*Adjusted for age, sex, education, father’s occupation, country of birth, asset index score, ever consumed alcohol 
†Adjusted for above confounders plus systolic blood pressure, diastolic blood pressure, and in analyses of the effects of ART 
treatment status, viral load. 
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Table 1.4. Association of HIV status by ART use status with cognitive scores using a three-level 
categorical variable of HIV-positive ART users vs. HIV-positive ART non-users vs. HIV-negative 
participants with HIV-negative participants as reference. 
 Model 1 Model 2 
Conventional measure   
HIV-negative Ref. Ref. 
HIV-positive ART user 0.06 (-0.001 to 0.13) 0.07 (0.002 to 0.13) 
HIV-positive ART non-user 0.06 (-0.03 to 0.15) 0.07 (-0.03 to 0.16) 
Summary OCS-plus measure   
HIV-negative Ref Ref 
HIV-positive ART user -0.04 (-0.10 to 0.03) -0.03 (-0.09 to 0.04) 
HIV-positive ART non-user -0.07 (-0.17 to 0.03) -0.07 (-0.17 to 0.03) 
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Table 1.5. Associations between HIV status, ART use, and domain-specific cognitive function as 
measured on the OCS-Plus instrument, HAALSI, Agincourt, South Africa, 2015   
  Domain specific effect† 
 Main effect* Memory Language Visual-spatial Executive 
 Model 
1‡ 
Model 
2 
Model 
1 
Model 
2 
Model 
1 
Model 
2 
Model 1 Model 2 Model 
1 
Model 2 
HIV status           
   Negative  Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
   Positive -0.03  
(-0.09 
to 0.03) 
-0.03  
(-0.08 
to 0.03) 
-0.01  
(-0.09 
to 0.06) 
-0.01 
(-0.08 
to 0.07)  
-0.04 
(-0.12 
to 0.04) 
-0.04  
(-0.12 
to 0.04) 
-0.02 
(-0.10 to 
0.07) 
-0.02  
(-0.10 to 
0.07) 
-0.02 
(-0.10 
to 0.07) 
-0.02  
(-0.10 to 
0.07) 
ART 
status 
          
   Non-user Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
   ART user  0.03  
(-0.08 
to 0.13) 
0.01  
(-0.14 
to 0.16) 
0.10  
(-0.04 
to 0.24)   
0.08  
(-0.10 
to 0.26) 
-0.07  
(-0.22 
to 0.09) 
-0.07 
(-0.22 
to 0.09) 
-0.16  
(-0.32 to 
-0.01) 
-0.15  
(-0.32 to 
-0.01) 
-0.05  
(-0.20 
to 0.11) 
-0.05  
(-0.20 to 
0.11) 
*Without interaction term between measure and predictor 
†With interaction between measure and predictor  
‡Model 1 is adjusted for age, sex, education, country of origin, father’s occupation, asset index score, and alcohol ever use.  
Model 2 is further adjusted for blood pressure, and in those with HIV for the treatment analysis, viral load. 
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Table 1.6. Association of HIV status and treatment status with a summary OCS-Plus measure of 
cognition adjusted for confounders 
 
 Model 1* Model 2† 
HIV status (N = 4480)   
   HIV-Negative  Ref. Ref. 
   HIV-Positive (β, 95% CI) -0.03 (-0.10 to 0.03) -0.03 (-0.09 to 0.04) 
Treatment status among HIV-positive (N = 1020)  
   ART non-user  Ref. Ref. 
   ART user (β, 95% CI) 0.03 (-0.09 to 0.15) 0.01 (-0.17 to 0.19) 
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Table 1.7. Interaction between age and HIV in their association with cognition adjusted for confounders 
 Conventional measure OCS-Plus measure 
HIV-Negative Ref. Ref. 
HIV-Positive (β, 95% CI) 0.11 (0.05 to 0.18) -0.078 (-0.14 to 0.001) 
Centered Age (β, 95% CI) -0.021 (-0.024 to -0.019) -0.014 (-0.017 to -0.010) 
HIV-Positive: Age (β, 95% CI) 0.01 (0.004 to 0.014) -0.01 (-0.01 to 0.001) 
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Chapter 2 : HIV status and antiretroviral therapy as predictors of disability 
among older South Africans: Do the associations depend on body mass 
index? 
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Background 
People living with HIV (PLWH) may experience premature age-related disability [1-3].  Also, increased 
access to antiretroviral therapy (ART) has substantially increased the survival of PLWH into older age 
[4].  Consequently, age-related disability is an important concern for PLWH, their caregivers, and health 
systems in settings with high HIV prevalence [5, 6].   
In sub-Saharan Africa (SSA), the region with the world’s highest HIV prevalence, few population-based 
studies have described age-related disability in PLWH.  In the general population, HIV infection is often 
associated with poor health [7] and may through this or other pathways increase risk of disability.  In 
those with HIV, ART use improves health [8-10] and could thus reduce risk of age-related disability.  
There is very little empirical confirmation of these expected patterns, however, because few studies have 
been able to compare PLWH to HIV negative comparators and, PLWH, ART users to non-users.  Overall, 
the extent to which HIV increases risk of disability in older adults and whether ART use mitigates this 
effect remains unclear [11-15].   
ART use also often causes weight gain [16] and could counter-intuitively increase risk of age-related 
disability in PLWH through obesity.   Literature from high-income settings suggests that high BMI 
(compared to normal or low BMI) increases risk of disability [17].  This is also a concern in SSA, given 
the rapidly unfolding obesity epidemic [18].  However, HIV-infected patients in SSA often have high 
rates of malnutrition, which is strongly associated with negative health outcomes [19, 20].  A South 
African study, which assessed BMI among ART-treated PLWH (with at least 6 months of ART use) 
reported no association with disability, but neither the distribution of BMI nor its form (e.g., linear vs. 
flexible) in the analyses were reported [21].  However, a study of population-level trends in BMI 
following the introduction of ART found an overall decrease in BMI and suggested that increased 
survival of largely underweight PLWH may have masked any ART-related increases in BMI [22].   
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Without empirical data on the role of HIV in age-related disability, HIV treatment programs in SSA 
cannot adequately respond to the needs of an increasingly older population of PLWH.  Responses such as 
addition of rehabilitative programs to HIV care [23], making HIV treatment clinics more accessible to 
people with disability [8, 24, 25], and possibly novel interventions to prevent or delay age-related 
disability, will become more urgent as the burden of age-related disability increases.  For example, if BMI 
either modifies or mediates effects of HIV and/or ART on disability, care may be improved by 
monitoring and potentially intervening on factors influencing weight change.  Alternatively, if BMI 
merely modifies effects of HIV and/or ART on disability, groups at high risk of disability might be 
simply targeted with interventions to reduce disability even if those interventions do not weight change. 
The “Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South Africa” 
(HAALSI), a population-based cohort of older individuals in South Africa, is collecting data that could 
facilitate population-based analyses on HIV and age-related disability [26].  Two prior studies from 
HAALSI have reported on HIV infection as a correlate of limitations in activities of daily living (ADL), 
but their results differed [13, 15].  The studies were not specifically designed to address the effects of HIV 
on disability but suggest sensitivity to analytic decisions, especially how confounders for multivariable 
regression models are selected.  Neither study addressed the role of ART use or BMI.   
In the cross-sectional data currently available in HAALSI, if effects of HIV or ART depend on BMI, it is 
impossible to distinguish between BMI at cohort entry modifying HIV or ART effects on disability, 
versus BMI being a mechanism that links an HIV diagnosis or ART initiation to subsequent disability.  
However, either result is important for guiding care.  For example, groups at increased risk of disability 
may be identified.  Results may indicate whether interventions to directly address underweight or obesity 
should be prioritized.  Finally, the results may guide hypotheses for future longitudinal studies. We 
therefore aimed to evaluate the association of HIV and ART with ADL disability in the HAALSI sample 
of older African individuals, and to assess whether these associations depend on BMI, hypothesizing that 
in this setting both low and high BMIs might increase risk of disability.   
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Methods 
Study setting and ethics statement 
The data were from HAALSI, a population-based cohort study enrolling men and women aged at least 40 
years and living in Agincourt, Mpumalanga, South Africa.  The characteristics of this cohort have been 
previously reported [26].  Sampling was done from the 2013 census round under the MRC/Wits-
Agincourt Health and socio-Demographic Surveillance System (HDSS), which is part of the International 
Network for the Demographic Evaluation of Populations and their Health (INDEPTH).   
Ethics statement 
Participants provided written informed consent, and ethics committees at the University of the 
Witwatersrand, South Africa, the Harvard T.H. Chan School of Public Health, and the Mpumalanga 
Provincial Research and Ethics Office, approved HAALSI.  The ethics committee at UCSF also reviewed 
and approved our proposal to access and analyze HAALSI data. 
Design 
We performed a cross-sectional analysis of HAALSI baseline data restricting the analysis to participants 
who had biological HIV tests from dried blood spots (N = 4552 (90%) of 5059). 
Measures 
HIV and ART use were the primary predictors.  Biological measurements were used.  Dried blood spots 
were collected for HIV status, plasma HIV RNA levels (viral load), and drug measurements 
(emtricitabine and lamivudine), as previously described [28].  PLWH testing positive for either 
emtricitabine or lamivudine, two drugs that are used interchangeably in initial ART regimens were 
considered as ART users.  All participants with HIV were tested for HIV viral load.  Individuals testing 
negative for antiretroviral drugs but who were virally suppressed were considered ART users [27].   
As the effects of ART may depend on whether viral suppression is achieved, in addition to comparing 
ART users to non-users, we created an additional categorical predictor taking viral suppression into 
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consideration.  This variable grouped participants with HIV into: those that were virally suppressed, all of 
whom were considered treated (viral load <100 copies/ml) (N = 537), vs. those that were treated but 
unsuppressed (positive for ART but with detectable viral load at the ≥100 copies/ml cut-off) (N = 183), 
vs. those that were untreated (negative for ART and with viral load ≥100 copies/ml) (N = 321) [28]. 
BMI was calculated from measured weight and height and considered as a potential mediator and/or 
modifier of the effects of HIV infection and of ART treatment, acknowledging that the temporal order is 
uncertain in a cross-sectional data set. We categorized BMI values as per previous studies [19, 20] into 
underweight (<18.5kg/m2), normal BMI (18.5 to <25), overweight (25 to <30) and obese (≥30). 
Limitation in any of 5 basic ADLs was assessed as the primary outcome.  Participants were asked about 
their ability to perform the following activities: walking across the room, dressing, bathing, using the 
toilet and getting out of bed.  Participants were classified as being disabled on an activity if they were 
unable to perform the activity; had difficulty performing the activity; used equipment when performing 
the activity; or received help from another person to perform the activity.  The final outcome measure was 
a binary variable describing presence of at least one disability versus none [13]. 
We represented our assumptions guiding covariate selection for the analyses using a DAG (Figure 2.1).  
Increasingly, most PLWH will receive ART regardless of their characteristics in the setting of “test and 
treat”, the current approach to HIV treatment [29].  However, treatment is not yet universal in South 
Africa and sociodemographic factors may influence the timing of ART initiation.  Covariates considered 
as potential confounders in all regression models were age and sex [30].  A second group of covariates 
obtained from study interviews was added to a more comprehensively adjusted regression model (model 
2).  These covariates included father’s occupation (professional, self-employed, business, or services, vs. 
manual labor, other or don’t know) to capture influences of cross-generational social status, and country 
of origin (South Africa vs. Mozambique or other), since the study area borders Mozambique and migrant 
residents may have been differentially exposed to structural health risk factors [31].  We also adjusted in 
these regression models for the participant’s own education (no formal education or some primary 
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education vs. some secondary education, or full secondary education or more) to account for possible 
education-related differences, and alcohol consumption ever in the participant’s life to account for 
possible differences in risk behaviors. 
Statistical analysis 
Based on logistic regression models, we estimated the marginal mean prevalence (Stata 15, College 
Station, Texas) of ADL disability comparing participants with HIV to those without HIV, and, among 
participants with HIV, ART users to non-users.  In additional analyses considering the viral load, we 
compared suppressed ART users vs. unsuppressed ART users vs. non-users.  BMI was conceptualized as 
either a potential mediator or effect modifier, but we could not distinguish between these alternatives.   
For each primary predictor (HIV or ART use), we fit a regression model adjusting for age and sex (model 
1), and a regression model further adjusting for education, father’s occupation, country of origin, and 
alcohol ever use (model 2).   
We estimated models with and without an interaction term between BMI and the primary predictor.  
Estimates from the interaction models are reported as marginal predictions of the prevalence of ADL 
disability in strata of the primary predictors and BMI categories with associated prevalence differences 
(estimated with Stata 15).  Covariates were centered at their mean values.  HIV negative participants with 
normal BMI and ART users with normal BMI were the reference categories for the HIV and ART 
predictors respectively.  When comparing suppressed ART users vs. unsuppressed ART users vs. ART 
non-users among PLWH, suppressed ART users were the reference category.  In additional analyses, we 
assessed both age and BMI modeled flexibly as restricted cubic splines in logistic regression models 
(estimated with R Statistical Software) predicting probability of an ADL disability in participants with 
HIV and those without HIV.  Observations from these analyses are presented graphically.   
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Results 
Sample characteristics 
Among 4552 participants included in the analyses, 1040 (23%) were PLWH.  Exclusions from the main 
sample (N = 5059) were: not tested for HIV (N = 477), indeterminate HIV test results (N = 22), and ART 
use not established (N = 8).  Among PLWH, 719 (69%) were ART users.  PLWH were younger (mean 
age 55 (SD = 10) vs 64 (SD = 13)), more likely to be underweight (7.4% vs. 4.6% in those without HIV) 
and less likely to be obese (21% vs 30%) than those without HIV.  Among PLWH, ART users were 
slightly more likely to be underweight than non-users (7.5% vs. 6.5%, respectively).  Among all 
participants, the proportion with an ADL disability was 11.9% (8.6% in PLWH vs. 12.9% in those 
without HIV) (Table 2.1). 
HIV status, BMI and ADL disability 
Adjusting for confounders underweight participants had higher prevalence of ADL disability than normal 
BMI participants (Tables 2.2 and 2.3).  For example, underweight PLWH had 13.3 percentage points 
(95% CI 3.8 to 22.9) higher prevalence of an ADL disability than PLWH with normal BMI.  Participants 
with obesity had 2.9 percentage points (95% CI: -2.3 to 8.1) higher prevalence of an ADL disability than 
those with normal BMI, this result not reaching statistical significance (Table 2.3).  Predicted probability 
of an ADL disability was elevated for HIV-negative participants at low BMI (Figure 2.2). 
ART use, BMI and ADL disability among PLWH 
Among PLWH, adjusting for confounders, underweight ART users also had higher prevalence of an ADL 
disability (Tables 2.4 and 2.5).  For example, underweight ART users had 13.7 percentage points (95% 
CI 2.8 to 24.4) higher prevalence of an ADL disability than normal weight ART users.  Overweight ART 
non-users had 5.2 percentage points (95% CI: -2.8 to 13.1) higher prevalence of an ADL disability, this 
result not reaching statistical significance.  Obese ART users had 1.2 percentage points (95% CI -4.3 to 
6.9) higher prevalence of an ADL disability than those with normal BMI, this result not statistically 
significant (Table 2.5).   
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The effects of ART use somewhat varied according to BMI and viral load categories although sample 
sizes for these additional analyses were small.  For example, adjusting for age and sex, underweight 
suppressed ART users had 16.0 percent points (95% CI 2.8 to 30.1) higher prevalence of an ADL 
disability than normal BMI suppressed ART users.  Overweight ART non-users had 6.0 percentage points 
(95% CI -2.2 to 14.2) higher prevalence of an ADL disability than normal BMI suppressed ART users, 
this result not reaching statistical significance (Supplementary table 1.2).   For all PLWH (treated 
suppressed, treated unsuppressed, and untreated PLWH), predicted probability of an ADL limitation was 
generally higher at low BMIs compared to normal or high BMIs (Figure 2.3). 
The independent associations of HIV and ART use with ADL disability 
In covariate-adjusted regression models without the interaction of HIV and ART with BMI, prevalence of 
an ADL disability was similar between PLWH and participants without HIV (adjusted prevalence 
difference (APD) 0.8 percentage points, 95% CI -1.8 to 3.4).  Among PLWH, ART users had similar 
prevalence of ADL disability as non-users (APD 0.5, 95% CI, -3.1 to 4.2).  Treated suppressed PLWH 
were as likely to have an ADL disability as treated unsuppressed, or untreated participants (APD 2.2, 95% 
CI -2.7 to 7.2 comparing unsuppressed ART users vs. suppressed ART users, and APD 0.03, 95% CI -3.8 
to 3.8 comparing ART non users to suppressed ART users) (Supplementary table 2.2).   
The independent association of age and BMI with ADL disability 
Prevalence of ADL disability increased with age for all participants (APD per SD increase in age = 4.0, 
95% CI 3.2 to 4.8) (Supplementary table 2.3).  However, at no age did the predicted prevalence of 
disability diverge substantially for people with vs without HIV (Figure 2.4).  Adjusting for HIV status 
and other covariates, underweight participants had 4.7 percent points (95% CI 0.5-8.9) higher prevalence 
of an ADL disability than normal BMI participants.  Obese participants had about 1.6 percentage points 
(95% CI: -0.7 to 3.9) higher prevalence of an ADL disability than those with normal BMI, this result not 
reaching statistical significance (Supplementary table 2.3).  
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Discussion 
In this population-based sample of older adults in rural South Africa, participants with HIV overall had 
similar prevalence of an ADL disability as those without HIV.  Among the participants with HIV, ART 
users also had similar prevalence of ADL disability as non-users.  However, regardless of HIV status, 
ART use or viral suppression, underweight participants had increased prevalence of an ADL disability. 
The association of HIV and ART with disability thus depended on BMI values, but given the cross-
sectional nature of these data, we cannot distinguish between BMI acting as a mediator versus BMI acting 
as a modifier of the effects of HIV and ART on ADL disability.  In a mediating role, underweight status 
would act as a mechanism linking HIV and/or ART to subsequent disability.  Interventions to increase 
weight such as nutritional supplementation might then be hypothesized as able to reduce risk of disability.  
This is a possibility since HIV infection is strongly associated with malnutrition in SSA [19].  
Malnutrition in HIV infection is also linked to muscle-weakness [32], a potential cause of ADL disability.   
Alternatively, if BMI merely modifies the effect of HIV or ART on disability, an important question is 
whether there are groups of HIV-positive or HIV-negative individuals for whom disability occurs only in 
presence of certain BMI values.  Population-level interventions against disability (regardless of whether 
such intervention affect weight) might then target such groups.  Observing such groups may also shed 
some light on potential mechanisms via which HIV and ART influence disability.   
Our results indicate that disability occurs more frequently in underweight groups irrespective of HIV 
status, ART use, or viral load.  Targeting underweight individuals with some interventions may thus be 
reasonable.  The content of such interventions should be addressed by future studies.  There are very few 
prior studies in the region that have investigated BMI or other measures of nutritional status as predictors 
of age-related disability.  However, in a cross-sectional study of PLWH in South Africa, low albumin, a 
nutrition-status biomarker was associated with functional limitations [33].  As we are unable to establish a 
causal role for BMI, we cannot say that interventions changing BMI would reduce risk of disability.  
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Moreover, factors causing low BMI may be nutritional but could also be due to underlying diseases such 
as tuberculosis, which would need to be identified and treated.   
Prior data suggest that ART may protect against ADL disability.  In a previous study among PLWH 
conducted in South Africa, rural participants on ART were 17% less likely to require assistance with 
instrumental activities of daily living (IADL) than counterparts not receiving ART at any clinic visit 
adjusting for multiple covariates (age, gender, education, marital status, income, healthcare utilization and 
the CD4+ T cell count).  Urban-living ART users were 41% less likely to require assistance than their 
counterparts not using ART.  ART users also had longer time to first IADL assistance in a Kaplan Meier 
analysis [9].  ART may protect against ADL disability since it generally improves the health of PLWH 
[10].   
Despite these observations in prior studies, we did not see higher prevalence of ADL disability among 
ART non-users overall.  ART non-users in our data were probably healthier than ART users; under earlier 
HIV care guidelines healthier individuals may have been deemed as “not yet eligible for ART”.  Selection 
can also occur within ART non-users, whereby any unhealthy individuals in the sub-group may have died 
prior to the HAALSI baseline sampling.  This pattern tends to bias observations conservatively, and may 
have led to the observation of no difference by ART use status.  The strong association of underweight 
with ADL disability and high rates of underweight among ART users could also mask benefits from 
ART.   
We did not find evidence for increased risk of disability from obesity or overweight, which was 
surprising, since studies from high-income countries suggest that obesity is a risk factor for age-related 
disability.  In the systematic review by Jiang et al (2018), obesity and overweight were associated with 
disability [17].  Underweight was also associated with disability in some of the studies [34, 35].  In our 
data, we also did not find differences overall by viral suppression status.  As detectable viral load has 
been previously associated with ADL disability [6], this association should be further investigated in 
future longitudinal studies. 
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Our observations are limited by the cross-sectional nature of the data, hence inability to establish a 
temporal structure among the variables.  However, a strengths of our study is biological HIV and ART 
measurements resulting in low risk of measurement error as a possible explanation for the observations.  
Despite their cross-sectional nature, our data add to the few population-based analyses available in SSA 
on the role of HIV in age-related disability and highlight the importance of underweight status in this 
population.   
Our findings suggest the need for interventions to reduce age-related disability for all sub-groups in this 
population.  However, underweight participants appear to be at an increased risk compared to everyone 
else and PLWH are more likely to be underweight.  This observation suggests that targeting underweight 
PLWH for interventions to reduce disability may be a reasonable choice.  Despite a relatively high 
prevalence of obesity in older South Africans, we did not find evidence for increases in disability from 
this risk factor.  We recommend future longitudinal studies to further investigate BMI and ART effects, 
especially in the setting of early treatment for PLWH. 
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Figure 2.1a. HIV versus disability Figure 2.1b. ART versus disability 
 
 
Figure 2.1. Directed acyclic graphs for possible relationships between HIV infection and treatment with 
antiretroviral therapy (ART) and disability 
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Figure 2.2. Smoothed relationships between BMI and predicted probability of an ADL disability among 
HIV-negative individuals in the HAALSI baseline sample (N = 3512). BMI was modelled as a 4-knots 
restricted cubic spline in logistic regression models predicting the probability of at least one ADL 
disability.  Models were adjusted for age and sex.  
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Figure 2.3. Smoothed relationships between BMI and predicted probability of an ADL disability by 
treatment and viral load status among participants with HIV (N = 1040).  BMI was modelled as a 4-knots 
restricted cubic spline in logistic regression models predicting the probability of at least one ADL 
disability.  Models were adjusted for age and sex. 
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Figure 2.4. Smoothed relationship between age and predicted probability of an ADL disability by HIV 
status among HAALSI participants at baseline (N = 4452).  Age was modelled as a 4-knots restricted 
cubic spline in logistic regression models to predict the probability of at least one ADL 
disability. 
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Table 2.1. The baseline characteristics of 4452 older South African adults at entry into the “Health and 
Aging in Africa: A Longitudinal Study of an INDEPTH Community in South Africa” (HAALSI).   
Interviews and measurements occurred from November 2014 to November 2015. 
Variable* 
All HIV 
positive  
(N = 1040) 
HIV positive - 
Treated  
(N = 719) 
HIV positive - 
Untreated  
(N = 321) 
HIV negative 
(N = 3512) 
Age, mean (SD) 55 (10) 56 (10) 55 (11) 64 (13) 
Sex, female 561 (54%) 339 (47%) 140 (44%) 1898 (54%) 
Log-10 viral load, mean 
(SD) 
1.8 (1.8) 0.87 (1.3) 3.7 (0.98) - 
Viral load category     
   Virally suppressed† 536 (52%) 536 (75%) - - 
   Unsuppressed 183 (18%) 183 (25%) - - 
   ART non-user 321 (30%) - 321 (100%) - 
Education     
   No formal education 427 (42%) 286 (40%) 141 (44%) 1660 (47%) 
   Some primary 359 (35%) 263 (37%) 96 (30%) 1225 (35%) 
   Some secondary 161 (15%) 107 (15%) 54 (17%) 345 (9.8%) 
   Secondary or more 89 (8.6%) 609 (8.0%) 29 (9.0%) 272 (7.7%) 
Country of origin     
   South Africa 679 (65%) 477 (66%) 202 (63%) 2486 (71%) 
   Other 359 (35%) 240 (33%) 119 (37%) 1024 (29%) 
BMI (in kg/m2)     
   <18.5 75 (7.4%) 54 (7.5%) 21 (6.5%) 160 (4.6%) 
   18.5-<25 449 (43%) 312 (43%) 137 (43%) 1133 (32%) 
   25 -<30 259 (25%) 184 (26%) 75 (23%) 971 (28%) 
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Variable 
All HIV 
positive  
(N = 1040) 
HIV positive - 
Treated  
(N = 719) 
HIV positive - 
Untreated  
(N = 321) 
HIV negative 
(N = 3512) 
   ≥30 223 (21%) 145 (20%) 78 (24%) 1064 (30%) 
   Missing 34 (3.3%) 24 (3.3%) 10 (3.1%) 184 (5.2%) 
Fathers occupation     
   Don’t know 83 (8.0%) 48 (6.7%) 35 (11%) 412 (12%) 
   Manual labor 583 (56%) 414 (58%) 169 (53%) 1950 (55%) 
   Other 129 (12%) 83 (12%) 46 (14%) 387 (11%) 
   Professional 106 (10%) 73 (11%) 33 (10%) 302 (8.6%) 
   Self-employed or business 34 (3.3%) 22 (3.1%) 12 (8.1%) 111 (3.2%) 
   Services 104 (10%) 78 (11%) 26 (8.1%) 349 (9.9%) 
Alcohol ever 467 (45%) 339 (53%) 193 (60%) 1564 (45%) 
Basic ADL limitation, N 
(%) 
    
   Walk across room 76 (7.3%) 56 (7.8%) 20 (6.2%) 406 (12%) 
   Dressing 27 (2.6%) 22 (3.1%) 5 (1.6%) 133 (3.8%) 
   Bathing 31 (3.0%) 25 (3.5%) 6 (1.9%) 152 (4.3%) 
   Getting out of bed 35 (3.4%) 26 (3.6%) 9 (2.8%) 209 (6.0%) 
   Using toilet 42 (4.0%) 31 (4.3%) 11 (3.4%) 255 (7.3%) 
  Any limitation 89 (8.6%) 63 (8.8%) 26 (8.1%) 453 (12.9%) 
*N (%) unless otherwise stated;   †viral load <100 copies/ml
45 
 
Table 2.2. Prevalence differences and 95% confidence intervals for one or more limitations in 5 basic 
activities of daily living, by BMI category and HIV status (Model 1).  Estimates adjusted for age and 
sex (model 1).  Analysis among HAALSI baseline sample (N = 4452).    
  
 HIV Negative HIV positive 
BMI 
Prevalence of 1+ADL 
disability 
Prevalence 
difference 
Prevalence of 
1+ADL disability 
Prevalence 
difference 
   Underweight 11.6 (7.2 to 16.1) 2.7 (-2.0 to 7.4) 23.7 (13.8 to 33.7) 14.8 (4.8 to 24.9) 
   Normal 8.9 (7.4 to 10.5) Ref. 9.3 (6.3 to 12.4) 0.4 (-3.0 to 3.8) 
   Overweight 8.8 (7.1 to 10.5) 0.1 (-2.4 to 2.2) 9.6 (5.4 to 13.7) 0.6 (-3.8 to 5.1) 
   Obese 9.6 (7.8 to 11.4) 0.7 (-1.7 to 3.1) 11.3 (6.5 to 16.1) 2.4 (-2.8 to 7.5) 
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Table 2.3. Prevalence differences and 95% confidence intervals for one or more limitations in 5 basic 
activities of daily living, by BMI category and HIV status (Model 2).  Estimates adjusted for age, sex, 
education, country of origin, father’s occupation, and alcohol ever use (model 2).  Analysis 
among HAALSI baseline sample (N = 4452).    
 
 HIV Negative HIV positive 
BMI 
Prevalence of 1+ADL 
disability 
Prevalence 
difference 
Prevalence of 
1+ADL disability 
Prevalence 
difference 
   Underweight 10.8 (6.6 to 14.9) 2.0 (-2.3 to 6.5) 22.0 (12.6 to 31.3) 13.3 (3.8 to 22.8) 
   Normal 8.7 (7.2 to 10.2) Ref. 9.0 (6.0 to 11.9) 0.3 (-3.0 to 3.6) 
   Overweight 8.6 (6.9 to 10.3) -0.1 (-2.3 to 2.2) 9.5 (5.4 to 13.6) 0.8 (-3.6 to 5.3) 
   Obese 10.0 (8.1 to 11.9) 1.3 (-1.1 to 3.8) 11.5 (6.6 to 16.4) 2.9 (-2.3 to 8.1) 
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Table 2.4. Adjusted prevalence differences and 95% confidence intervals for one or more limitations in 5 
basic activities of daily living (1+ADL) by BMI category and ART use status among people living with 
HIV (Model 1).  Estimates adjusted for age and sex (model 1).  Analysis among HAALSI baseline sample 
(N = 1040).    
 ART non-user ART user 
BMI 
Prevalence of 
1+ADL disability 
Prevalence 
difference 
Prevalence of 
1+ADL disability 
Prevalence 
difference 
Underweight 9.2 (0 to 21.4) 2.1 (-10.4 to 14.5) 21.7 (10.8 to 32.7) 14.6 (3.4 to 25.9) 
Normal 5.8 (1.9 to 9.7) -1.3 (-6.2 to 3.5) 7.1 (4.3 to 10.0) Ref. 
Overweight 12.4 (4.9 to 20.0) 5.3 (-2.8 to 13.4) 4.4 (1.4 to 7.4) -2.7 (-6.9 to 1.4) 
Obese 8.3 (1.9 to 14.6) 1.1 (-5.9 to 8.2) 7.7 (3.3 to 12.1) 0.6 (-4.7 to 5.9) 
  
48 
 
Table 2.5. Adjusted prevalence differences and 95% confidence intervals for one or more limitations in 5 
basic activities of daily living (1+ADL) by BMI category and ART use status among people living with 
HIV (Model 2).  Estimates adjusted for age, sex, education, father’s occupation, country of origin, and 
alcohol ever use (model 2), HAALSI baseline sample (N = 1040).    
 ART non-user ART user 
BMI 
Prevalence of 
1+ADL disability 
Prevalence 
difference 
Prevalence of 
1+ADL disability 
Prevalence 
difference 
Underweight 8.7 (0 to 20.2) 1.7 (-10.2 to 13.5) 20.7 (10.1 to 31.3) 13.7 (2.8 to 24.4) 
Normal 5.6 (1.8 to 9.4) -1.4 (-6.1 to 3.3) 7.0 (4.2 to 9.8) Ref. 
Overweight 12.9 (5.1 to 20.6) 5.8 (-2.5 to 14.1) 4.4 (1.4 to 7.3) -2.7 (-6.8 to 1.4) 
Obese 8.9 (2.1 to 15.7) 1.9 (-5.6 to 9.3) 8.4 (3.6 to 13.1) 1.2 (-4.3 to 6.9) 
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Supplementary table 2.1. Prevalence differences for at least one ADL disability by ART use and viral 
load group and BMI category adjusted for age and sex.  Analysis among HAALSI participants at baseline 
(n=1040). 
 1+ADL disability, prevalence difference 
BMI 
Suppressed 
ART user 
Unsuppressed 
ART user 
ART non-user 
Underweight 16.5 (2.8 to 30.1) 12.5 (-6.8 to 31.8) 2.8 (-9.8 to 15.3) 
Normal Ref. 2.4 (-4.3 to 9.1) 0.1 (-5.7 to 4.4) 
Overweight -3.0 (-7.3 to 1.4) 1.0 (-7.7 to 9.7) 6.0 (-2.2 to 14.2) 
Obese 1.6 (-4.5 to 7.6) 0.1 (-9.3 to 9.5) 1.8 (-5.4 to 8.9) 
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Supplementary table 2.2.  HIV status, ART use, and ART use by viral load and prevalence differences 
for ADL disability adjusting for confounders among HAALSI participants at baseline (N = 4452) 
  Model 1*  Model 2** 
Predictor Prevalence 1+ADL 
Disability, 
Prevalence 
difference 
Prevalence 1+ADL 
Disability, 
Prevalence 
difference 
HIV status     
   Negative 11.7 (10.7 to 12.7) Ref. 11.7 (10.7 to 12.7) Ref. 
   Positive 12.8 (10.4 to 15.2) 1.1 (-1.5 to 3.7) 12.6 (10.2 to 14.9) 0.9 (-1.7 to 3.5) 
ART status     
   Non-user 8.3 (5.3 to 11.4) Ref. 8.5 (5.4 to 11.5) Ref 
   ART user 8.7 (6.6 to 10.7) 0.3 (-3.3 to 4.0) 8.8 (6.2 to 11.3) 0.2 (-3.5 to 3.9) 
ART by viral load     
   Suppressed ART user 8.1 (5.8 to 10.4) Ref. 8.1 (5.8 to 10.4) Ref. 
   Unsuppressed ART 
user 
10.3 (6.0 to 14.7) 2.2 (-2.7 to 7.2) 10.3 (6.0 to 14.7) 2.2 (-2.7 to 7.2) 
   Non-user 8.3  (5.3 to 11.4) 0.2 (-3.6 to 4.0) 8.5 (5.4 to 11.5) 0.3 (-3.5 to 4.2) 
*Adjusted for age, sex; **Adjusted for age, sex, education, father’s occupation, country of origin, and alcohol ever use 
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Supplementary table 2.3. The independent association of age and BMI with ADL disability: predicted 
prevalence and prevalence differences of 1+ADL disability by different values of age and BMI among 
HAALSI participants at baseline 
 1+ADL disability, prevalence difference 
Predictor value Model 1 Model 2 
Age (per SD change) 4.3 (3.6 to 5.0) 4.0 (3.2 to 4.8) 
BMI   
   Underweight 5.6 (1.1 to 10) 4.8 (0.6 to 8.9) 
   Normal Ref. Ref. 
   Overweight 0.01 (-2.1 to 2.1) 0.1 (-2.0 to 2.1) 
   Obese 0.9 (-1.3 to 3.1) 1.6 (-0.7 to 3.9) 
*Adjusted for age (SD = 13 years), sex and HIV status; **Adjusted for age, sex, HIV status, education, father’s occupation, 
country of origin and alcohol ever use 
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Chapter 3 : Is antiretroviral therapy alone sufficient to eliminate excess 
mortality related to Kaposi’s sarcoma among HIV-infected adults in sub-
Saharan Africa? 
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Background 
Antiretroviral therapy (ART) has dramatically changed the face of HIV-associated Kaposi’s sarcoma 
(KS).  In both high-resource settings, where potent combination ART first emerged in 1996, and, more 
recently, in low-resource settings, ART has decreased KS incidence and improved population-level 
survival after KS diagnosis [34-36].  In fact, one of the most remarkable aspects of the introduction of 
ART were case reports of patients with KS who had their lesions shrink or completely resolve with ART 
alone, without any adjunctive therapy [37].  This formed the basis of the common practice in high-
resource settings of using ART alone to treat KS that does not have immediately life-threatening 
complications [38, 39].  
ART alone as initial therapy for KS is also practiced in low-resource settings, such as sub-Saharan Africa, 
but this is largely based upon the successes seen in high-resource settings and a practical response to the 
unaffordability of chemotherapy.  The lack of direct evidence for this approach in sub-Saharan Africa is 
concerning given that the stakes can be viewed as considerably higher.  In sub-Saharan Africa, the 
underlying endemicity of Kaposi’s sarcoma-associated herpesvirus (the causative agent of KS) in the 
general population [40-42] has led to KS being common among all HIV-infected individuals [43], not just 
a sub-set as is seen in resource-rich settings such as the U.S, Europe, and Australia [44].  In recent data 
from sub-Saharan Africa, KS is the third most common cancer amongst all men and the fifth most 
common amongst all women [45, 46].  That the approach of ART alone for initial therapy of KS is 
successful in high-resource settings is not necessarily sufficient to justify it in Africa.   The ample 
differences in KSHV strain [47, 48], HIV strains [49], human host, paradoxical responses to ART [50], 
and medical care infrastructure (e.g., availability of chemotherapy in case initial ART fails) between high-
resource settings and sub-Saharan Africa cast doubt on the wisdom of extrapolating treatment approaches 
and suggest that direct data from Africa are needed.  
To evaluate the strategy of initial therapy with ART alone for KS in sub-Saharan Africa, we studied 
survival in persons with AIDS-related KS initially treated with ART alone and a carefully assembled 
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comparable group of HIV-infected African adults without KS also initiated on ART.  We sought to 
address whether initial use of ART alone is able to eliminate any excess mortality related to KS.  While 
equivalent survival would justify continuation of the current approach of management, a residual 
mortality risk from KS would indicate that additional interventions are required over and above ART. 
Methods 
Study population and setting 
Individuals with KS were participants in the Antiretrovirals for Kaposi’s sarcoma (ARKS), a clinical trial 
performed at the Infectious Diseases Institute (IDI) in Kampala, Uganda (2007 to 2011) to assess whether 
ART regimens with protease inhibitors (PIs) were superior to regimens without PIs in treating KS.  The 
participants were recruited from throughout Uganda and had biopsy confirmed KS without immediately 
life threatening complications.  Those with indications for immediate chemotherapy such as 
mucocutaneous KS (bulky lesions ≥5cm diameter, ulcerated skin lesions, or oral lesion interfering with 
swallowing), suspected pulmonary or gastrointestinal KS (abnormal, and otherwise unexplained, chest x-
ray, a positive occult blood stool test, or history of overt bleeding from the mouth or rectum), and 
lymphedema of the face or other body region resulting in symptoms or functional disability were 
excluded.  Also, participants who had concurrent untreated opportunistic infections or other non-KS 
malignancy, or unexplained high temperature (> 38.5o C) were excluded.   
Participants without KS were from the Uganda AIDS Rural Treatment Outcomes (UARTO) cohort 
(2005-2015), a prospective study of HIV-infected adults designed to assess various outcomes following 
ART initiation.  They were initiating ART for indications other than KS at the Immune Suppression 
Syndrome clinic in Mbarara, Uganda.  A small number (n=16) who had KS that had been clinically 
diagnosed were excluded to avoid diagnostic heterogeneity and consequent measurement bias.   
Both groups were followed from the time of ART initiation (time 0) until either death or administrative 
closure at 4 years.  ARKS and UARTO were approved by institutional review committees at Makerere 
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University, MUST, the University of California San Francisco, and the Massachusetts General Hospital.  
The studies are also registered with formal prospective study registers. 
Measurements 
Primary predictor 
The primary predictor was biopsy confirmed KS.  Trained study personnel performed 4mm punch 
biopsies of two representative skin KS lesions on each patient, which were sent to the pathology 
laboratory for a histological diagnosis.  If initial histology was uncertain, the slides were reviewed by a 
second pathologist.  For few participants with only oral lesions, where a biopsy was deemed to pose 
substantial risk, a visual diagnosis confirmed by two study physicians sufficed.  
Outcome 
The primary outcome was mortality.  As there is no national death index in Uganda, we established 
mortality through physically tracking patients in the community and obtaining reports from relatives 
and/or friends.  For all the ARKS participants, and for UARTO participants who missed their quarterly 
appointments, community tracking was performed.  A subject was considered lost as of their last contact 
with the study or clinic, if they were not known to have died, and no contact could be established with 
them for ≥180 days. 
Predictor covariates 
Socio-demographic and clinical information was collected using the same questionnaires for both groups.  
We measured socio-economic status using an asset index score [51, 52].  Clinical measurements included 
a history of serious opportunistic infections such as tuberculosis (TB), oro-esophageal candidiasis, and 
cryptosporidial diarrhea and the body mass index (BMI).  A physical health summary score (PHS) was 
calculated for each participant from responses to the Medical Outcomes Survey-HIV questionnaire [53].  
Laboratory studies were performed for both groups at the same laboratory (the Makerere John-Hopkins 
University collaboration core laboratory at IDI, Kampala) and included the hemoglobin level 
(Humacount, Human Diagnostics Worldwide, Wiesbaden, Germany); CD4+ T cell counts (FACSCount 
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System, BD Biosciences, San Jose, CA); and plasma HIV RNA levels (Roche Amplicor; Roche 
Diagnostics, Indianapolis, Indiana, USA).  
Statistical analysis 
We first used Kaplan Meier techniques to describe survival by group.  We then performed multivariable-
adjusted analyses using proportional hazards regression to determine the independent effect of being 
diagnosed with KS at ART initiation on survival.  We adjusted for confounders of this relationship using 
a directed acyclic graph (DAG)-based approach [54].  To account for HIV disease progression, which is 
unmeasured, we adjusted for multiple proxies of the same variable that had been measured at ART 
initiation (Figure 3.1).  Calendar time of ART initiation was one of the variables we had identified in the 
DAG as an important confounder.  However, as the two groups were not overlapping on this variable, we 
performed one analysis adjusting for all measured confounders and proxies except calendar time, and 
another adjusting for all measured confounders and proxies including the calendar date of ART initiation.  
In addition to estimating hazard ratios of mortality by KS group, we calculated the adjusted absolute 
difference in the risk of mortality between the two groups at 4 years.  
To check the assumptions of this analysis, we calculated scores of the propensity to be diagnosed with KS 
diagnosis by group based on all the covariates that were adjusted for; we examined these scores for 
positivity violations i.e., whether a substantial number of patients in either group had 0 or 100% 
probability of being diagnosed with KS.  Also, we performed Schoenfeld tests and plotted the mortality 
hazard against follow-up time to assess proportionality of the hazard over time.  As non-proportionality 
was found to be present i.e., mortality hazard changed substantially over time, we split follow-up time 
into two periods (0-1 year, and 1-4 years).   Finally, we tested for the interaction of KS with CD4 T cell 
count and hemoglobin level.   
After missing values were obtained from source documents whenever possible, we imputed any 
remaining missing values using iterative chained equations (ICE); we included in the imputation 
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equations variables with complete data (KS diagnosis, sex, history of tuberculosis, mortality, and 
observation time) and an interaction term between mortality and observation time.  As we did not impute 
any missing outcomes, we performed sensitivity analyses assessing the impact that the limited number of 
losses to follow-up might have had on our results.  We expected that loss to follow-up would not bias our 
inferences unless it acted differentially by exposure group.  Hence, we assessed two extreme scenarios 
assuming death rates to be different by group in those lost to follow-up.  In the first scenario, we assumed 
that all lost died only if they had KS; in the second, we assumed that all lost died only if they did not have 
KS.  Mortality hazard ratios were recalculated under these assumptions.  We also performed another 
sensitivity analysis assessing the impact of excluding participants, in both groups, who were in non-
overlapping regions of the propensity to develop KS.  All analyses were performed in Stata 13 
(StataCorp, Texas, USA) 
 
Results 
Subject characteristics at ART initiation 
From 2005 to 2013, we enrolled 224 participants with KS and 683 participants without KS.  Enrollment 
for KS participants occurred in 2008-2010; enrollment for non-KS participants spanned a longer period 
(2006-2012).  Median age was 34 years (IQR: 28-40) in both groups.  The KS group had more males 
(56% versus 30%, p<0.001), lower physical health summary scores (median 53.2, IQR 36.4-58.2, versus 
55.4, IQR 46.1-59.5, p<0.001), lower CD4+ T-cell counts (median 119, IQR 24-265/mm3 versus 168 IQR 
96-263, P<0.001), and higher plasma HIV RNA (median 5.4 IQR 5.0-5.6 log10 copies/ml versus 5.0, IQR 
4.5-5.5 log10 copies/ml, p<0.001) (Table 3.1).  None of the KS participants were considered to have 
clinically relevant visceral disease.  Initial ART regimens were mainly tenofovir-based in the KS group 
(tenofovir with emtricitabine and ritonavir/lopinavir or efavirenz).  This was unlike the no-KS group, 
where the majority received zidovudine-based regimens (zidovudine with lamivudine and nevirapine or 
efavirenz). 
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Unadjusted analysis 
Participants were followed for a maximum of 4 years.  For the KS group, median follow-up time was 2.4 
years (IQR 1.3-3.3), with cumulative loss to follow up (in a competing risk analysis where mortality was 
the competing risk) estimated at 2% at 1 year and 6% at 4 years (Figure 3.5).  In the group without KS, 
median follow-up time was 4.0 years (IQR 1.5-4.0), with cumulative loss to follow-up estimated at 8% at 
1 year and 11% at 4 years.  Cumulative mortality at 4 years was 30% in the KS group compared to 8.2% 
in the no-KS group (Figure 3.2).  Mortality hazard varied across follow-up time being highest in the first 
year following ART initiation, and declining sharply afterwards, but remaining higher at all times in the 
KS group (Figure 3.3).  In the unadjusted analysis, participants with KS had 5.2-fold (95% CI, 3.2-8.5, 
p<0.001) higher hazard of death in year 1, and 2.7-fold (95% CI, 1.3-5.7, p=0.008) higher hazard of death 
in years 2 to 4 compared to those without KS (Table 3.2). 
Adjusted analysis 
Adjusting for 12 measured confounders (age, sex, asset holding, date of ART initiation, history of TB, 
oro-esophageal candidiasis, and cryptosporidial diarrhea, the physical health summary score, BMI, 
hemoglobin, CD4+ T-cell count, and plasma HIV RNA level), participants with KS had 3.7-fold (95% 
CI, 2.1-6.7, p=<0.001) in year 1, and 2.2-fold (0.97-4.8, p=0.061) in years 2 to 4 higher hazard of death 
compared to participants without KS in a model not adjusting for calendar time (Table 2).  After further 
adjusting for calendar time, the HR comparing participants with KS to those without KS increased to 5.0 
(95% CI, 2.5-10.0, p=<0.001) in year 1, and  2.9 (95% CI, 1.2-7.0, p=0.020) in the years 2 to 4 period 
(Table 3.2). 
Predictions of mortality risk from KS given ART  
In estimating predicted risk of death given a KS diagnosis at ART initiation, a prototypical HIV-infected 
participant with KS had about 0.19 risk of death at 1 year (Figure 3.4).  In comparison, a prototypical 
participant without KS had a much lower risk of about 0.04.  At 4 years, the estimated risk of death for a 
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prototypical participant with KS was 0.29 compared to 0.083 for a prototypical participant without KS.  
This suggests a residual risk of 0.20 at 4 years of follow up. 
Interactions 
We tested for interactions between KS and CD4 and between KS and HB and found no evidence of such 
interactions (p=0.998, and p=0.972, respectively).   
Sensitivity analyses  
To assess the sensitivity of our results to losses to follow-up, we explored extreme mortality scenarios in 
those lost to follow-up.  The first scenario assumed that among those lost to follow-up, all with KS died 
while none without KS died.  In this scenario, the estimated HR increased to 5.9 (95% CI, 2.9-11.9, 
p=<0.001) in the first year of follow-up, and 3.3 (95% CI, 1.4-7.9, p=0.008) in years 2 to 4.  In scenario 2, 
we assumed that among those lost to follow-up, none with KS died and all without KS died.  In this 
scenario, the estimated HR decreased to 2.8 (95% CI 1.6-4.9, p= <0.001) in the first year, and 0.88 (95% 
CI, 0.42-1.8, p=0.72) in years 2 to 4.  These extreme scenarios are unlikely in the real world, but, notably, 
even in the most extreme (and effectively most unlikely) scenario relevant to our inference where all lost 
to follow-up in the non-KS group are assumed to have died, while all lost to follow up the KS group 
survive, participants with KS remain at a substantially higher risk of death in the first year of follow up.   
Additional sensitivity analyses, excluded patients whose propensity scores for a KS diagnosis given 
measured confounders was in regions of non-overlap (Figures 3.6 and 3.7).  Specifically, we excluded 
participants with propensity scores ≤0.03, and those with propensity scores ≥0.88, where, based on a 
visual examination of histograms of the distributions of the propensity for having a KS diagnosis among 
KS and non-KS participants, regions outside these bounds did not have sufficient comparators in either 
group (≤4).  This excluded from the analysis 441 participants from the no-KS group leaving only 242, and 
99 participants from the KS group leaving only 125.  A comparison of the remaining participants in a 
model adjusting for calendar time yielded largely similar results as the non-restricted analysis; the HR 
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comparing participants with KS to those without KS was 4.9 (95% CI, 1.9-12.6, p=0.001) in year 1, and 
2.2 (95% CI, 0.68-7.3, p=0.183) in years 2 to 4. 
Discussion 
Previous studies have not accurately quantified the impact of ART on mortality from HIV-associated KS.  
In particular, for low-resource settings like SSA, where HIV-positive patients with early KS are often 
initially treated with ART alone, it is unclear whether ART alone can eliminate any excess mortality from 
KS and thus whether additional interventions over and above ART are required for such patients.  Among 
HIV-infected adults initiating ART in Uganda, we tested the hypothesis that given ART, residual risk of 
mortality from KS becomes zero.  Despite comprehensive adjustment to account for HIV disease 
progression at ART initiation, the risk of mortality following ART initiation remained about 5-fold higher 
in the first year among participants with KS compared to participants without KS.  ART alone was not 
sufficient to eliminate excess mortality from KS suggesting the need for additional interventions over and 
above ART for patients with KS.  Findings further suggest need for better prognostic classifications of KS 
since individuals with KS judged as low-risk at ART initiation had much higher mortality than 
comparable individuals without KS. 
ART alone might fail to eliminate excess mortality from KS for several reasons.  Among patients with 
KS, ART may have variable impact at the individual level.  In particular, for patients in whom certain 
biological features of KS are present, e.g., excessive inflammation, additional treatments (e.g., anti-
inflammatory agents) might be needed to supplement the beneficial effects of ART.  Studies directly 
evaluating the role of inflammation in HIV-associated KS outcomes are still lacking, but KSHV, the 
causative agent of KS is known to be associated with inflammation [55].  Studies have also linked HHV8 
replication with progressive KS disease [56] and suggest that KSHV-associated inflammation may 
increase immediately after ART [57].  Whereas previous studies from high-resource settings have 
reported substantial reductions in KS-related mortality following widespread ART use [34, 35, 58-60], 
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the population-level effects observed in these settings may have been partly influenced by non-ART 
factors (e.g., efficacious chemotherapy, radiotherapy and overall quality of health-care services.  In 
previous studies from SSA, many of which did not adjust for as many confounders and are affected by 
high rates of loss to follow-up, mortality risk is consistently higher in patients with KS initiating ART 
than in other patients [61-67].   
In our study, there was a precipitously high rate of mortality in the first year of ART initiation.  The 
immune reconstitution syndrome (IRIS) is a possible explanation for this observation [68].  Although 
there are no confirmatory studies, some previous studies suggest that IRIS is more common and more 
strongly associated with mortality in African patients compared to patients in high-resource settings [69].  
An alternative explanation is natural disease progression in absence appropriate adjunctive therapy.  
Assuming that chemo, which was available in ARKS, or its timing, were not sufficient, patients with a KS 
diagnosis might naturally rapidly decline and die in the first year of observation, despite ART [70]. 
Overall, mortality in our study was higher than what has been observed in high-resource settings, which, 
in addition to the precipitous death rates in the first year, may have other explanations.  Diagnostic 
limitations in Africa probably leave a substantial burden of KS disease undetected at ART initiation (i.e., 
underdiagnosis and sub-optimal staging in the KS group) [71].  Further, the prognostic significance of 
well-known KS characteristics such as edema may be underestimated.  In SSA, such risk factors could be 
indicative of worse underlying progression stage than in other settings [72].  The drivers of KS in sub-
Saharan Africa and the population that gets KS may be different from other settings. For example, KS in 
sub-Saharan Africa is more generalized at the population level than in resource-rich settings [73-75].  
There may thus be more heterogeneity in presenters, and generalized prognostic tools like the clinical 
criteria used to select participants into the KS group are less accurate and need to be more individualized.  
Finally, the lack of specific treatments for KS, when compared with other OIs which have OI-specific 
treatments, could make the survival of people with other OIs better compared to counterparts with KS.  
For example, patients with TB have access to treatments over and above ART; other OIs such as 
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esophageal candida and crypto diarrhea also often do not have specific treatments over and above ART, 
but these OIs may be more susceptible to ART alone than KS [76]. 
Our study has some limitations.  We were unable to control for ART regimen composition.  In theory, the 
ART regimens that were given to KS group may have been superior ─ more potent, and less toxic.  
However, we are not aware of any studies that have conclusively demonstrated superiority/inferiority of 
any of the ART regimens used.  Even then, since there was higher mortality in the KS group, the bias 
resulting from this would be conservative, implying that the true HR is higher than what we observed.  
Adjunctive chemotherapy was, in general, accessible for the patients in the KS group, which is not the 
case for other KS patients initiating ART in sub-Saharan Africa.  This also could imply that the observed 
mortality in the KS group is an underestimate of what actually happens to KS patients enrolling in routine 
care in sub-Saharan Africa.  This also is a conservative bias, implying that the true HR may be higher 
than what we observed.  The two populations are not strictly exchangeable because they were not 
sampled identically, and like in any observational study, there is potential for residual confounding.  To 
minimize such biases we performed comprehensive adjustment using as many as possible of the 
surrogates of HIV disease progression at ART initiation.  Moreover, measurements in both groups were 
done by the same laboratories and questionnaires to minimize systematic differences. 
In conclusion, among patients initiating ART in Uganda, ART alone did not eliminate excess mortality 
from KS in presenters initially treated with ART alone, implying that additional interventions were 
required over and above ART, as well as better prognostic staging of KS.  Our findings call for action to 
make efficacious adjunctive therapies available to all presenters with HIV-associated KS.  What these 
adjunctive therapies are, other than those already known such as chemotherapy and radiotherapy remains 
the subject of future studies.  Whether and how these therapies are used in individual patients, often a 
clinical decision, should also be subjected to further studies.  Accordingly, we recommend studies 
examining the precipitous rates of mortality in KS patients in the first year following ART initiation.  
Such studies should attempt to separate the role of IRIS from that of natural disease progression in the 
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absence of sufficient treatment.  This line of investigation may identify newer adjunctive therapies that 
are required for KS but are not yet being used.  Future studies should also develop more accurate 
prognostic classifications for KS patients in sub-Saharan Africa.  
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Figure 3.1. Directed acyclic graph (DAG) showing the hypothesized causal relationship between 
Kaposi’s sarcoma (KS) and mortality amongst HIV-infected adults who are about to initiate antiretroviral 
therapy (ART).  In this depiction, HIV disease progression is not directly measured but body mass index, 
hemoglobin, and physical health status summary are viewed as some of its proxy measurements along 
with socioeconomic status, opportunistic infections, and CD4+ T cell count. The present study seeks to 
determine whether a causal relationship between KS and mortality exists among patients treated initially 
with ART alone, thereby addressing whether ART alone is able to eliminate any excess mortality related 
to KS.   
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Figure 3.2. Unadjusted cumulative incidence of death over time amongst HIV-infected adults in Uganda 
following antiretroviral therapy (ART) initiation, by Kaposi’s sarcoma (KS) status. 
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Figure 3.3. Smoothed unadjusted hazard of mortality amongst HIV-infected adults in Uganda following 
antiretroviral therapy (ART) initiation, by Kaposi’s sarcoma (KS) status. 
 
 
 
  
67 
 
 
 
Figure 3.4. Predicted risk of death amongst HIV-infected adults in Uganda following antiretroviral 
therapy (ART) initiation, by Kaposi’s sarcoma (KS) status. Estimates are adjusted for age, sex, asset 
holding, history of tuberculosis, history of cryptosporidial diarrhea, history of esophageal candidiasis, 
physical health summary score, body mass index, hemoglobin, CD4+ T cell count, plasma HIV RNA 
level and calendar date of ART initiation (Model 2).  These predictions were obtained from a regression 
model that adjusted for all the listed covariates fixed on their population median values.  The predictions 
represent what the expected risk of death following ART initiation would be in a prototypical patient from 
this population if they had KS versus if they did not.  
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Figure 3.5. Cumulative incidence of becoming lost to follow-up amongst HIV-infected adults initiating 
antiretroviral therapy (ART) in Uganda, by Kaposi’s sarcoma (KS) status. 
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Figure 3.6. Distribution of propensity score of having a Kaposi’s sarcoma (KS) diagnosis, according to 
KS status, amongst HIV-infected adults in Uganda (Model 1). Estimates are based on covariates that 
were adjusted for in multivariable model 1 (age, sex, asset holding, history of tuberculosis, 
history of cryptosporidial diarrhea, history of esophageal candidiasis, physical health summary 
score, body mass index, hemoglobin, CD4+ T cell count, and plasma HIV RNA level).   
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Figure 3.7. Distribution of propensity score of having a Kaposi’s sarcoma (KS) diagnosis, according to 
KS status, amongst HIV-infected adults in Uganda (Model 2).  Estimates are based on covariates that 
were adjusted for in multivariable model 2 (age, sex, asset holding, history of tuberculosis, history of 
cryptosporidial diarrhea, history of esophageal candidiasis, physical health summary score, body mass 
index, hemoglobin, CD4+ T cell count, and plasma HIV RNA level, in addition to calendar date of 
antiretroviral therapy initiation). 
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Table 3.1. Characteristics of HIV-infected adults in Uganda at time of antiretroviral therapy (ART) 
initiation, by Kaposi’s sarcoma (KS) status. 
Variable 
KS Present 
(N=224) 
KS Absent 
(N=683)  
Age, years 34 (28 to 40)* 34 (28 to 40) 
Male sex 56% 30% 
Asset holding† 0.16 (-1.48 to 2.30) -1.41 (-2.29 to -0.20) 
Tuberculosis, history of 12% 9.2% 
Cryptococcal meningitis, history of 0.45% 1.2% 
Oro-esophageal candidiasis, history of  4.5% 13% 
Cryptosporidial diarrhea, history of  1.4% 8.6% 
Physical health score‡ 53.2 (36.4 to 58.2) 55.4 (46.1 to 59.5) 
Body mass index, kg/m2 21.4 (19.4 to 23.1) 21.2 (19.5 to 23.8) 
Hemoglobin, g/dl 11.8 (10.5 to 13.2) 12.6 (11.2 to 14.0) 
CD4+ T cells/μl 119 (24 to 265) 168 (96 to 263) 
HIV RNA, log10 plasma copies/ml 5.4 (5.0-5.6) 5.0 (4.5-5.5) 
Year of ART initiation   
   2005 - 7.6% 
   2006 - 18% 
   2007 8.9%§ 25% 
   2008 30% 14% 
   2009 31% 5.9% 
   2010 16% 1.5% 
   2011 1.3% 13% 
   2012 - 12% 
   2013 - 2.8% 
 
* Median (interquartile range) unless otherwise indicated  
† From the Filmer-Pritchett index, a marker of socio-economic status [51] 
‡ From the Medical Outcomes Study-HIV survey [53] 
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Table 3.2. Effect of Kaposi’s sarcoma (KS) diagnosis on subsequent mortality following initiation of 
antiretroviral therapy (ART) amongst HIV-infected adults in Uganda. 
Time after 
ART 
initiation 
 Unadjusted Model Adjusted Model 1* Adjusted Model 2† 
KS 
diagnosis 
Hazard Ratio 
(95% CI) 
P value 
Hazard Ratio 
(95% CI) 
P value 
Hazard Ratio* 
(95% CI) 
P value 
   Year 1 Absent Ref.  Ref.  Ref.  
 Present 5.2 (3.2-8.5) <0.001 3.7 (2.1-6.7) <0.001 5.0 (2.5-10.0) <0.001 
Year 2-4 Absent Ref.  Ref.  Ref.  
 Present 2.7 (1.3-5.7) 0.008 2.2 (0.97-4.8) 0.061 2.9 (1.2-7.0) 0.020 
 
*Adjusted for age, sex, asset holding, history of tuberculosis, history of cryptosporidial diarrhea, history of 
esophageal candidiasis, physical health summary score, body mass index, hemoglobin, CD4+ T cell count, and 
plasma HIV RNA level. 
†Adjusted for the same set of confounders as model 1 in addition to calendar date of ART initiation. 
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